
AIDP Gets Magnesium Patent for Metabolic Disorders
Typical metabolic disorders include, but are not limited to, obesity and diabetes.
AIDP (City of Industry, CA) has gained a U.S. patent for its branded ingredient
The patent, No. 8,163,301, is titled “Magnesium compositions and uses thereof for metabolic disorders.” It not only covers Magtein’s unique magnesium compositions but also the use of food, dietary supplements, and drugs containing magnesium L-threonate to combat the effects of metabolic disorder.
Typical metabolic disorders include, but are not limited to, obesity and diabetes. Magtein’s other patents lie in the area of neurological disorders (patent 8,142,803) and food compositions (patent 8,178,132).
Newsletter
From ingredient science to consumer trends, get the intel you need to stay competitive in the nutrition space—subscribe now to Nutritional Outlook.





